Inmune Bio, Inc. cash flow statement
In fiscal 2025, Inmune Bio, Inc.'s operations generated −$22.6m of cash; it spent $1.0m on capital projects, leaving free cash flow of −$23.6m.
Cash flow statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1 | −2 | −9 | −29 | −23 | −12 | −33 | −23 |
| Depreciation and amortisation | — | — | — | — | — | — | — | 0 |
| Stock-based pay | 0 | 10 | 3 | 5 | 7 | 7 | 8 | 10 |
| Capital spending | — | — | — | — | — | — | — | 1 |
| Free cash flow | — | — | — | — | — | — | — | −24 |
| Free cash flow after stock pay | — | — | — | — | — | — | — | −34 |
| Shares issued | 2 | 1 | 25 | 80 | 1 | 1 | 28 | 28 |
| Quarter | 2024 Q1Mar 2024 | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −7 | −8 | −7 | −11 | −7 | −7 | −5 | −3 |
| Depreciation and amortisation | — | — | — | — | — | — | — | 0 |
| Stock-based pay | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| Capital spending | — | — | — | — | — | — | 0 | 0 |
| Free cash flow | — | — | — | — | — | — | −6 | −3 |
| Free cash flow after stock pay | — | — | — | — | — | — | −9 | −6 |
| Shares issued | — | — | 12 | 0 | 5 | 22 | 0 | 0 |
Compare with peers
- Lyell Immunopharma, Inc. cash flow
- AIM Immunotech Inc. cash flow
- Ibio, Inc. cash flow
- Lisata Therapeutics, Inc. cash flow
- Celldex Therapeutics, Inc. cash flow
Head to head: INMB vs LYELAIM vs INMBIBIO vs INMB
More: Biotechnology stocks compared, Health Care sector, rankings of US companies